The latest price of targeted drug capmatinib in 2024

Capmatinib (Capmatinib) is a new generation of targeted therapy drugs that belongs to the category of small molecule kinase inhibitors. Its main function is to inhibit the activity of MET protein kinase, and has been widely studied and used in the treatment of patients with MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC).

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.

METexon14 skipping mutation is a rare but important genetic mutation that leads to abnormal activation of MET kinase, thereby promoting the growth and spread of tumors. Capmatinib blocks this abnormal signaling by specifically intervening in the MET pathway, thereby inhibiting the growth and metastasis of cancer cells.

Capmatinib is unique in that it specifically targets METexon14skipping mutantNSCLC, providing an effective option for targeted therapy for patients with this subtype. Clinical trial data show that capmatinib has demonstrated significant efficacy in this specific patient group, including improving the objective response rate and prolonging survival, bringing new treatment hope to patients.

In addition to its remarkable efficacy, capmatinib also raises safety concerns. During treatment, some patients may experience varying degrees of adverse reactions, such as fatigue, nausea, diarrhea, etc., which require close monitoring and management by the medical team.